RECRUITINGOBSERVATIONAL
Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis
Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning and With Single vs Repeated Effort in Myasthenia Gravis
About This Trial
Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction, characterized by fatigue, which increases gradually through the day. The repetitive nerve stimulation (RNS) remains the key diagnostic test in MG, however its sensitivity, especially in ocular form of MG is not satisfactory. In this study, investigators want to assess the impact of the time of the day on the sensitivity of the RNS. We hypothesize the RNS performed in the evening may be more sensitive than in the morning.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form)
- Patients with performed or planned determination of anti-AChrR and anti-MUSK antibodies.
- Disease severity of at least 1 in the classification of the severity of myasthenia gravis according to the recommendations of the Myasthenia Gravis Foundation of America
Who Should NOT Join This Trial:
- respiratory failure
- severe bulbar symptoms
- pharmacotherapy with substances that may worsen neuromuscular transmission disorders
- current infection
- coexisting diseases of the peripheral nervous system which may affect the result of the fatigue test, e.g. polyneuropathy or myopathy
- cognitive and behavioral disorders that may negatively affect patient's adherence to study protocol
- Medication with steroids due to myasthenia
- Severity of myasthenia that makes the discontinuation of acetylcholinesterase inhibitors unsafe.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form)
* Patients with performed or planned determination of anti-AChrR and anti-MUSK antibodies.
* Disease severity of at least 1 in the classification of the severity of myasthenia gravis according to the recommendations of the Myasthenia Gravis Foundation of America
Exclusion Criteria:
* respiratory failure
* severe bulbar symptoms
* pharmacotherapy with substances that may worsen neuromuscular transmission disorders
* current infection
* coexisting diseases of the peripheral nervous system which may affect the result of the fatigue test, e.g. polyneuropathy or myopathy
* cognitive and behavioral disorders that may negatively affect patient's adherence to study protocol
* Medication with steroids due to myasthenia
* Severity of myasthenia that makes the discontinuation of acetylcholinesterase inhibitors unsafe.
Locations (1)
Jagiellonian University Medical College, Department of Neurology
Krakow, Lesser Poland Voivodeship, Poland